870 related articles for article (PubMed ID: 16458520)
1. Isolation and characterization of a monoamine oxidase B selective inhibitor from tobacco smoke.
Khalil AA; Davies B; Castagnoli N
Bioorg Med Chem; 2006 May; 14(10):3392-8. PubMed ID: 16458520
[TBL] [Abstract][Full Text] [Related]
2. Tobacco leaf, smoke and smoking, MAO inhibitors, Parkinson's disease and neuroprotection; are there links?
Castagnoli K; Murugesan T
Neurotoxicology; 2004 Jan; 25(1-2):279-91. PubMed ID: 14697903
[TBL] [Abstract][Full Text] [Related]
3. Species-dependent differences in monoamine oxidase A and B-catalyzed oxidation of various C4 substituted 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridinyl derivatives.
Inoue H; Castagnoli K; Van Der Schyf C; Mabic S; Igarashi K; Castagnoli N
J Pharmacol Exp Ther; 1999 Nov; 291(2):856-64. PubMed ID: 10525109
[TBL] [Abstract][Full Text] [Related]
4. Human monoamine oxidase is inhibited by tobacco smoke: beta-carboline alkaloids act as potent and reversible inhibitors.
Herraiz T; Chaparro C
Biochem Biophys Res Commun; 2005 Jan; 326(2):378-86. PubMed ID: 15582589
[TBL] [Abstract][Full Text] [Related]
5. Isolation and characterization of a monoamine oxidase inhibitor from tobacco leaves.
Khalil AA; Steyn S; Castagnoli N
Chem Res Toxicol; 2000 Jan; 13(1):31-5. PubMed ID: 10649964
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotection in the MPTP Parkinsonian C57BL/6 mouse model by a compound isolated from tobacco.
Castagnoli KP; Steyn SJ; Petzer JP; Van der Schyf CJ; Castagnoli N
Chem Res Toxicol; 2001 May; 14(5):523-7. PubMed ID: 11368550
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate (NW-1772) as a highly potent, selective, reversible, and orally active monoamine oxidase B inhibitor.
Pisani L; Muncipinto G; Miscioscia TF; Nicolotti O; Leonetti F; Catto M; Caccia C; Salvati P; Soto-Otero R; Mendez-Alvarez E; Passeleu C; Carotti A
J Med Chem; 2009 Nov; 52(21):6685-706. PubMed ID: 19810674
[TBL] [Abstract][Full Text] [Related]
8. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
Gal S; Zheng H; Fridkin M; Youdim MB
J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of monoamine oxidase A and B activities by imidazol(ine)/guanidine drugs, nature of the interaction and distinction from I2-imidazoline receptors in rat liver.
Ozaita A; Olmos G; Boronat MA; Lizcano JM; Unzeta M; García-Sevilla JA
Br J Pharmacol; 1997 Jul; 121(5):901-12. PubMed ID: 9222546
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective aspects of a novel MAO-B inhibitor PF9601N.
Pérez V; Morón J; Pastó M; Unzeta M
Neurobiology (Bp); 2000; 8(3-4):231-6. PubMed ID: 11225513
[TBL] [Abstract][Full Text] [Related]
11. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and molecular modeling of some novel hexahydroindazole derivatives as potent monoamine oxidase inhibitors.
Gökhan-Kelekçi N; Simşek OO; Ercan A; Yelekçi K; Sahin ZS; Işik S; Uçar G; Bilgin AA
Bioorg Med Chem; 2009 Sep; 17(18):6761-72. PubMed ID: 19682910
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of monoamine oxidase by pirlindole analogues: 3D-QSAR analysis.
Medvedev AE; Ramsay RR; Ivanov AS; Veselovsky AV; Shvedov VI; Tikhonova OV; Barradas AP; Davidson CK; Moskvitina TA; Fedotova OA; Axenova LN
Neurobiology (Bp); 1999; 7(2):151-8. PubMed ID: 10591049
[TBL] [Abstract][Full Text] [Related]
14. Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors.
Shi L; Yang Y; Li ZL; Zhu ZW; Liu CH; Zhu HL
Bioorg Med Chem; 2010 Feb; 18(4):1659-64. PubMed ID: 20117937
[TBL] [Abstract][Full Text] [Related]
15. Monoamine oxidase B (MAO-B) inhibition by active principles from Uncaria rhynchophylla.
Hou WC; Lin RD; Chen CT; Lee MH
J Ethnopharmacol; 2005 Aug; 100(1-2):216-20. PubMed ID: 15890481
[TBL] [Abstract][Full Text] [Related]
16. Methylpiperate derivatives from Piper longum and their inhibition of monoamine oxidase.
Lee SA; Hwang JS; Han XH; Lee C; Lee MH; Choe SG; Hong SS; Lee D; Lee MK; Hwang BY
Arch Pharm Res; 2008 Jun; 31(6):679-83. PubMed ID: 18563347
[TBL] [Abstract][Full Text] [Related]
17. Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues.
Pretorius J; Malan SF; Castagnoli N; Bergh JJ; Petzer JP
Bioorg Med Chem; 2008 Sep; 16(18):8676-84. PubMed ID: 18723354
[TBL] [Abstract][Full Text] [Related]
18. Contribution of monoamine oxidase (MAO) inhibition to tobacco and alcohol addiction.
van Amsterdam J; Talhout R; Vleeming W; Opperhuizen A
Life Sci; 2006 Oct; 79(21):1969-73. PubMed ID: 16884739
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationships in the inhibition of monoamine oxidase B by 1-methyl-3-phenylpyrroles.
Ogunrombi MO; Malan SF; Terre'blanche G; Castagnoli N; Bergh JJ; Petzer JP
Bioorg Med Chem; 2008 Mar; 16(5):2463-72. PubMed ID: 18065227
[TBL] [Abstract][Full Text] [Related]
20. Dramatic species differences in the susceptibility of monoamine oxidase B to a group of powerful inhibitors.
Krueger MJ; Mazouz F; Ramsay RR; Milcent R; Singer TP
Biochem Biophys Res Commun; 1995 Jan; 206(2):556-62. PubMed ID: 7826372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
